Securities code: 301096 securities abbreviation: Baicheng pharmaceutical Announcement No.: 2022025 Hangzhou Baicheng Pharmaceutical Technology Co., Ltd
Announcement on the company’s profit distribution plan for 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “the company”) held the second meeting of the third board of directors and the second meeting of the third board of supervisors on March 13, 2022, deliberated and adopted the proposal on the company’s profit distribution plan in 2021. The relevant matters are hereby announced as follows:
1、 Profit distribution plan in 2021
According to the audit report with unqualified opinion of TJS [2022] No. 808 issued by Tianjian Certified Public Accountants (special general partnership), the net profit attributable to the shareholders of the parent company in 2021 was 11108825350 yuan. According to the relevant provisions of the company law and the articles of association, the statutory surplus reserve of 1169694939 yuan was withdrawn, plus the undistributed profit of 6390304005 yuan at the beginning of the year. As of December 31, 2021, the company’s distributable profit was 16329434416 yuan.
In view of the good operation of the company at present, combined with the future development prospect of the company, on the premise of ensuring the normal operation and long-term development of the company, in accordance with the company law, the articles of association and the three-year plan for shareholders’ dividend return (20212023) promised before the company’s initial public offering and listing, in order to repay all shareholders, The company’s profit distribution plan for 2021 is to distribute cash dividends of 6.00 yuan (including tax) to all shareholders for every 10 shares based on the total share capital of 108166667 shares on December 31, 2021, with a total of 649 China Vanke Co.Ltd(000002) 0 yuan. The remaining undistributed profits will be accumulated for distribution in subsequent years. No bonus shares will be given in this year and no capital reserve will be converted into share capital.
If the total share capital changes before the equity registration date of equity distribution, the company plans to maintain the distribution proportion per share unchanged and adjust the total distribution accordingly. The profit distribution plan complies with the profit distribution policy stipulated in the articles of association and the company’s shareholder return plan.
2、 Approval opinions and procedures of this scheme
1. Opinions of the board of directors
The board of directors agreed with this plan and considered that the profit distribution plan for 2021 proposed by the company was in line with the relevant provisions on profit distribution in the company law and the articles of association, the profit distribution policy determined by the company, the long-term return plan of shareholders and relevant commitments made by the company, and matched with the actual operation, performance and future development of the company, The annual profit distribution plan submitted to the general meeting of minority shareholders is reasonable for the sustainable development of the company, especially for the legitimate and stable interests of the company, which will damage the actual interests of the company.
2. Opinions of the board of supervisors
The board of supervisors agreed with the plan and considered that the profit distribution plan for 2021 proposed by the company was in line with the actual situation of the company, better took into account the immediate and long-term interests of shareholders on the premise of ensuring the normal operation and long-term development of the company, and there was no violation of laws, regulations and the articles of association, There is no damage to the interests of shareholders, especially small and medium-sized shareholders, which is conducive to the sustainable, stable and healthy development of the company.
3. Opinions of independent directors
In view of the proposal on the company’s profit distribution plan for 2021 prepared by the board of directors of the company, we believe that the plan is a decision made according to the actual situation of the company, which not only takes into account the needs of the company’s normal operation and long-term development, but also takes into account the interests of shareholders, and embodies the principle of the company’s positive return to shareholders. Therefore, we unanimously agree to the company’s proposal on the company’s profit distribution plan for 2021 and submit it to the company’s 2021 annual general meeting for deliberation.
3、 Relevant risk tips
The profit distribution plan comprehensively considers the company’s profitability, business development and reasonable return to shareholders, and will not have a significant impact on the company’s operating cash flow and the normal operation and development of the company. This profit distribution plan can only be implemented after being submitted to the 2021 annual general meeting of shareholders of the company for deliberation and approval. Please pay attention to the investment risks.
4、 Documents for future reference
1. Resolutions of the second meeting of the third board of directors;
2. Resolutions of the second meeting of the third board of supervisors;
3. Independent opinions of independent directors on matters related to the second meeting of the third board of directors.
It is hereby announced.
Board of directors of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. March 13, 2022
